Inventiva SACA

Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022

16 июн 2022 15:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022

09 июн 2022 15:00:00 Источник Nasdaq GlobeNewswire

Inventiva joins the Euronext Tech Leaders segment

07 июн 2022 15:00:00 Источник Nasdaq GlobeNewswire

 Inventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association

03 июн 2022 15:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces participation at several investors conferences in May and June 2022

23 май 2022 15:00:00 Источник Nasdaq GlobeNewswire

Results of the votes of the Combined Shareholders’ Meeting of May 19, 2022

20 май 2022 15:00:00 Источник Nasdaq GlobeNewswire

Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 19 May 2022

19 май 2022 15:00:00 Источник Nasdaq GlobeNewswire

Inventiva reports 2022 First Quarter Financial Information and provides clinical development update

16 май 2022 15:00:00 Источник Nasdaq GlobeNewswire

Inventiva secures a €50 million credit facility from the European Investment Bank

16 май 2022 01:00:00 Источник Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital as of April 11, 2022

28 апр 2022 09:35:00 Источник Nasdaq GlobeNewswire

Combined General Meeting of May 19, 2022 - Availability of the preparatory documents

28 апр 2022 09:30:00 Источник Nasdaq GlobeNewswire

 Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver

07 апр 2022 15:00:00 Источник Nasdaq GlobeNewswire

 Inventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F

11 мар 2022 15:44:49 Источник Nasdaq GlobeNewswire

 Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA

08 мар 2022 01:00:00 Источник Nasdaq GlobeNewswire

Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis

07 мар 2022 15:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces participation at several conferences in March 2022

01 мар 2022 15:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results

28 фев 2022 15:00:00 Источник Nasdaq GlobeNewswire

Inventiva reports cash position and revenues for Full-Year 2021

14 фев 2022 15:00:00 Источник Nasdaq GlobeNewswire

Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation

31 янв 2022 15:00:00 Источник Nasdaq GlobeNewswire

Inventiva announces participation at several conferences in January and February 2022

20 янв 2022 15:00:00 Источник Nasdaq GlobeNewswire